Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 …
A Du Bois, G Kristensen, I Ray-Coquard… - The Lancet …, 2016 - thelancet.com
Background Angiogenesis is a target in the treatment of ovarian cancer. Nintedanib, an oral
triple angiokinase inhibitor of VEGF receptor, platelet-derived growth factor receptor, and …
triple angiokinase inhibitor of VEGF receptor, platelet-derived growth factor receptor, and …
Does hysteroscopy facilitate tumor cell dissemination? Incidence of peritoneal cytology from patients with early stage endometrial carcinoma following dilatation and …
A Obermair, M Geramou, F Gucer, U Denison… - Cancer, 2000 - Wiley Online Library
BACKGROUND In several case reports, distension and irrigation of the uterine cavity during
fluid hysteroscopy was suspected to cause tumor cell dissemination into the abdominal …
fluid hysteroscopy was suspected to cause tumor cell dissemination into the abdominal …
Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide …
P Dubsky, P Sevelda, R Jakesz, H Hausmaninger… - Clinical cancer …, 2008 - AACR
Purpose: To determine the effects of anemia on local relapse-free, relapse-free, and overall
survival (LRFS, RFS, and OS, respectively) in premenopausal, primary breast cancer …
survival (LRFS, RFS, and OS, respectively) in premenopausal, primary breast cancer …
Normalized LST is an efficient biomarker for homologous recombination deficiency and Olaparib response in ovarian carcinoma
Y Christinat, L Ho, S Clément, C Genestie… - JCO Precision …, 2023 - ascopubs.org
PURPOSE The efficiency of the Myriad Homologous Recombination Deficiency (HRD) test
to guide the use of poly (ADP-ribose) polymerase (PARP) inhibitors has been demonstrated …
to guide the use of poly (ADP-ribose) polymerase (PARP) inhibitors has been demonstrated …
[HTML][HTML] Discordance between GCIG CA-125 progression and RECIST progression in the CALYPSO trial of patients with platinum-sensitive recurrent ovarian cancer
DS Zebic, A Tjokrowidjaja, KE Francis… - British Journal of …, 2024 - nature.com
Background CA-125 alone is widely used to diagnose progressive disease (PD) in platinum-
sensitive recurrent ovarian cancer (PSROC) on chemotherapy. However, there are …
sensitive recurrent ovarian cancer (PSROC) on chemotherapy. However, there are …
Incidence of anaemia in breast cancer patients receiving adjuvant chemotherapy
U Denison, J Baumann, C Peters-Engl… - Breast cancer research …, 2003 - Springer
Anaemia is frequent in breast cancer patients but often remains undiagnosed and untreated.
To determine the incidence of anaemia a prospective survey of primary non-metastatic …
To determine the incidence of anaemia a prospective survey of primary non-metastatic …
Lunar phases and survival of breast cancer patients–a statistical analysis of 3,757 cases
C Peters-Engl, W Frank, F Kerschbaum… - Breast cancer research …, 2001 - Springer
The potential influence of lunar phases on human life has been widely discussed by the lay
press. The purpose of this study was to find out whether the timing of surgery during …
press. The purpose of this study was to find out whether the timing of surgery during …
Oestrogen and progesterone receptor content as a prognostic factor in advanced epithelial ovarian carcinoma
P SEVELDA, U DENISON… - … Journal of Obstetrics …, 1990 - Wiley Online Library
Levels of oestrogen receptor (ER) and progesterone receptor (PgR) in ovarian cancer tissue
were examined with regard to their prognostic importance for survival in 179 patients with …
were examined with regard to their prognostic importance for survival in 179 patients with …
2022-RA-567-ESGO The Geneva HRD test: clinical validation on 469 samples from the PAOLA-1 trial
Y Christinat, L Ho, S Clément, C Genestie, J Sehouli… - 2022 - ijgc.bmj.com
Introduction/Background The efficacy of the Myriad myChoice® Homologous Recombination
Deficiency (HRD) test to guide use of PARP inhibitors has been demonstrated in several …
Deficiency (HRD) test to guide use of PARP inhibitors has been demonstrated in several …
[PDF][PDF] GIInger predicts homologous recombination deficiency and patient response to PARPi treatment from shallow genomic profiles
Homologous recombination deficiency (HRD) is a predictive biomarker for poly (ADP-ribose)
polymerase 1 inhibitor (PARPi) sensitivity. Routine HRD testing relies on identifying BRCA …
polymerase 1 inhibitor (PARPi) sensitivity. Routine HRD testing relies on identifying BRCA …